148 related articles for article (PubMed ID: 25322975)
1. Is postmenopausal hormone replacement therapy suitable after a cardio- or cerebrovascular event?
Windler E; Stute P; Ortmann O; Mueck AO
Arch Gynecol Obstet; 2015 Jan; 291(1):213-7. PubMed ID: 25322975
[TBL] [Abstract][Full Text] [Related]
2. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
L'Hermite M
Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.
Schneider C; Jick SS; Meier CR
Climacteric; 2009 Oct; 12(5):445-53. PubMed ID: 19565370
[TBL] [Abstract][Full Text] [Related]
4. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women.
Dinger J; Bardenheuer K; Heinemann K
Climacteric; 2016 Aug; 19(4):349-56. PubMed ID: 27174159
[TBL] [Abstract][Full Text] [Related]
5. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.
Simon JA
Climacteric; 2012 Apr; 15 Suppl 1():3-10. PubMed ID: 22432810
[TBL] [Abstract][Full Text] [Related]
6. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis.
Anagnostis P; Galanis P; Chatzistergiou V; Stevenson JC; Godsland IF; Lambrinoudaki I; Theodorou M; Goulis DG
Maturitas; 2017 May; 99():27-36. PubMed ID: 28364865
[TBL] [Abstract][Full Text] [Related]
7. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Mueck AO
Climacteric; 2012 Apr; 15 Suppl 1():11-7. PubMed ID: 22432811
[TBL] [Abstract][Full Text] [Related]
8. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone therapy and the risk of cardiovascular disease.
Stramba-Badiale M
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
[TBL] [Abstract][Full Text] [Related]
12. [Indications for hormone replacement therapy].
Birkhäuser MH
Ther Umsch; 2000 Oct; 57(10):635-42. PubMed ID: 11081375
[TBL] [Abstract][Full Text] [Related]
13. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
Ettinger B; Pressman A; Bradley C
Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
[TBL] [Abstract][Full Text] [Related]
14. Benefits of hormone replacement therapy in postmenopausal women.
Canderelli R; Leccesse LA; Miller NL; Unruh Davidson J
J Am Acad Nurse Pract; 2007 Dec; 19(12):635-41. PubMed ID: 18042129
[TBL] [Abstract][Full Text] [Related]
15. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
Johansen OE; Qvigstad E
Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
[TBL] [Abstract][Full Text] [Related]
16. [Basic principles of hormone replacement therapy in the postmenopause].
Dören M
Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.
Simon JA; Laliberté F; Duh MS; Pilon D; Kahler KH; Nyirady J; Davis PJ; Lefebvre P
Menopause; 2016 Jun; 23(6):600-10. PubMed ID: 26953655
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
Canonico M
Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
[TBL] [Abstract][Full Text] [Related]
19. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
[TBL] [Abstract][Full Text] [Related]
20. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
Renoux C; Dell'aniello S; Garbe E; Suissa S
BMJ; 2010 Jun; 340():c2519. PubMed ID: 20525678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
